FindTrial
Sign In

Therapeutic drug monitoring-guided dose adjustment of rivaroxaban in patients with nonvalvular atrial fibrillation: a randomized controlled trial.

Therapeutic drug monitoring-guided dose adjustment of rivaroxaban in patients with nonvalvular atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033767
Enrollment
Unknown
Registered
2020-06-11
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonvalvular atrial fibrillation

Interventions

experimental group:TDM Pharmaceutical Service
control group:Conventional treatment

Sponsors

Shanghai Jiaotong University Affiliated Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Non-valvular atrial fibrillation patients taking rivaroxaban with risk factors for bleeding.

Exclusion criteria

Exclusion criteria: Patients with rivaroxaban contraindications or taking medication for a short time.

Design outcomes

Primary

MeasureTime frame
Plasma Concentration of Rivaroxaban;Anti-FXa activity;—

Countries

China

Contacts

Public ContactLi Xingxia

Shanghai Jiaotong University Affiliated Sixth People's Hospital

chraysan@126.com+86 18930173923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026